ORKA Stock Analysis: Oruka Therapeutics | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 7.250m USD | 12M Return: 299.4% | US6876041087 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 87.2M
Warnings
Tailwinds
Seasonality 11.9 years of data, until 10/2026
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, ≥40 worth a closer look and ≥60 is strong.
Oruka Therapeutics, Inc. is a clinical-stage biopharmaceutical company headquartered in Menlo Park, California, that develops novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. The company is classified within the GICS Biotechnology sub-industry, and as a clinical-stage enterprise it has no approved products on the market and typically relies on capital markets and potential future partnerships to fund its research and development activities.
Orukas lead pipeline candidates include ORKA-001, which targets the p19 subunit of interleukin-23 and is currently in a Phase 2a trial for PsO, and ORKA-002, which targets interleukin-17A and interleukin-17F and is in a Phase 2 trial for PsO, psoriatic arthritis, and additional conditions. The company is also advancing ORKA-003, which targets an undisclosed pathway, and ORKA-021, a sequential combination regimen pairing ORKA-002 with ORKA-001. Monoclonal antibodies targeting IL-23 and IL-17 pathways represent a competitive and well-established segment of the immunology biologics market, with several approved therapies already addressing these mechanisms.
- ORKA-001 Phase 2 psoriasis data readout approaches
- Competition intensifies from Skyrizi and Tremfya in IL-23 market
- Cash burn raises dilution risk as clinical trials advance
| Net Income: error (cannot be calculated; needs Net Income TTM and Revenue TTM) |
| FCF/TA: -0.10 > 0.02 and ΔFCF/TA 6.55 > 1.0 |
| NWC/Revenue: error (cannot be calculated; needs Current Assets/Liabilities and Revenue current+prev) |
| CFO/TA -0.10 > 3% & CFO -123.6m > Net Income -152.6m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 29.62 > 1.5 & < 3 |
| Outstanding Shares: last quarter (71.6k) vs 12m ago -99.84% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 0.0% > 50% (prev 0.0%; Δ 0.0% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBIT TTM and Interest Expense TTM) |
| A: 0.74 (Total Current Assets 941.5m - Total Current Liabilities 31.8m) / Total Assets 1.23b |
| B: -0.25 (Retained Earnings -312.1m / Total Assets 1.23b) |
| C: -0.20 (EBIT TTM -173.6m / Avg Total Assets 870.1m) |
| D: 35.34 (Book Value of Equity 1.20b / Total Liabilities 33.9m) |
| Altman-Z'' = 39.79 = AAA |
As of November 14, 2026, the stock is trading at USD 105.35 with a total of 679,677 shares traded. Over the past week, the price has changed by +2.42%, over one month by +34.74%, over three months by -2.56% and over the past year by +299.36%.
Current recommended Stop Loss: 92.70 (which is 12% or 2.2 ATR below the current price).
Oruka Therapeutics has received a consensus analysts rating of 4.85. Therefore, it is recommended to buy ORKA.
- StrongBuy: 11
- Buy: 2
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 156.2 | 48.2% |
P/B = 6.2295
Revenue TTM = 0.0 USD
EBIT TTM = -173.6m USD
EBITDA TTM = -173.5m USD
Long Term Debt = 2.09m USD (estimated: total debt 2.93m - short term 838k)
Short Term Debt = 838k USD (from shortTermDebt, last quarter)
Debt = 2.93m USD (from shortLongTermDebtTotal, last quarter) (leases 2.93m already included)
Net Debt = -917.3m USD (calculated: Debt 2.93m - CCE 920.3m)
Enterprise Value = 6.33b USD (7.25b + Debt 2.93m - CCE 920.3m)
Interest Coverage Ratio = unknown (Ebit TTM -173.6m / Interest Expense TTM 0.0)
EV/FCF = -51.13x (Enterprise Value 6.33b / FCF TTM -123.9m)
FCF Yield = -1.96% (FCF TTM -123.9m / Enterprise Value 6.33b)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 83.0k) / Revenue TTM)
Tobins Q-Ratio = 5.14 (Enterprise Value 6.33b / Total Assets 1.23b)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 2.93m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -137.2m (EBIT -173.6m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 29.62 (Total Current Assets 941.5m / Total Current Liabilities 31.8m)
Debt / Equity = 0.00 (Debt 2.93m / totalStockholderEquity, last quarter 1.20b)
Debt / EBITDA = 5.29 (negative EBITDA) (Net Debt -917.3m / EBITDA -173.5m)
Debt / FCF = 7.41 (negative FCF - burning cash) (Net Debt -917.3m / FCF TTM -123.9m)
Total Stockholder Equity = 817.6m (last 4 quarters mean from totalStockholderEquity)
RoA = -17.53% (Net Income -152.6m / Total Assets 1.23b)
RoE = -18.66% (Net Income TTM -152.6m / Total Stockholder Equity 817.6m)
RoCE = -21.18% (EBIT -173.6m / Capital Employed (Equity 817.6m + L.T.Debt 2.09m))
RoIC = -11.43% (negative operating profit) (NOPAT -137.2m / Invested Capital 1.20b)
WACC = 7.81% (E(7.25b)/V(7.25b) * Re(7.81%) + D(2.93m)/V(7.25b) * Rd(0.0%) * (1-Tc(0.21)))
Discount Rate = 7.81% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 37.53 | Cagr: -90.56%
[DCF] Fair Price = unknown (Cash Flow -123.9m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.12 | # QB: 0
Revenue Correlation: N/A | Revenue CAGR: N/A | SUE: 0.0 | # QB: 0
EPS current Quarter (2027-03-31): EPS=-0.73 | Chg30d=-0.58% | Revisions=-38% | Analysts=5
EPS current Year (2026-12-31): EPS=-2.52 | Chg30d=-6.34% | Revisions=-58% | GrowthEPS=-36.0% | GrowthRev=+0.0%
EPS next Year (2027-12-31): EPS=-2.94 | Chg30d=-2.87% | Revisions=-25% | GrowthEPS=-17.0% | GrowthRev=+0.0%
[Analyst] Revisions Ratio: -50% (up=5, down=18)